DEVIN SCANNELL

SENIOR VICE PRESIDENT, DRUG DISCOVERY

The convergence of synthetic biology and biopharma is going to be an enormous driver of innovation.

Prior to Zymergen, Devin was an Associate Partner at McKinsey & Co where his clients ranged from Top 20 pharma to 20-person biotechs. He co-led the McKinsey Precision Medicine Initiative and advised on novel drug modalities among many other topics. He has also held operating roles in strategy, finance and M&A. Previously, Devin was a Postdoctoral Fellow at UC Berkeley where he applied data science techniques to very large genomics datasets. He received his Ph.D. in Evolutionary Genomics and B.A. in Human Genetics from Trinity College, Dublin. He has first author papers in Nature and Cell.